Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents

Pharmacogenomics

Volumn 15, Issue 3, 2014, Pages 375-384

  Kim, Hark Kyun ^a   Green, Jeffrey E ^b  

^a National Cancer Center   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

biomarker; chemotherapy; gastric cancer; predictive marker; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CYTOTOXINS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84894442315     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.250     Document Type: Review

References (75)

1. Alberts S, Cervantes A, van de Velde C. Gastric cancer: epidemiology, pathology, and treatment. Ann. Oncol. 14(Suppl. 2), ii31-ii36 (2003).
2. Bang YJ, van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010).
3. Shitara K, Doi T, Ohtsu A. Molecular targeting therapy and biomarker for advanced gastric cancer. J. Phys. Chem. Biophys. 2, 107-112 (2012).
4. Gordon MA, Gundacker HM, Benedetti J et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann. Oncol. 24(7), 1754-1761 (2013).
5. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29(36), 4803-4810 (2011).
6. Rüschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457(3), 299-307 (2010).
7. Bang Y. A randomized, open-label, Phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J. Clin. Oncol. 30(Suppl. 34) (2012) (Abstract 11).
8. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7), 797-805 (2008).
9. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4), 395-402 (2007).
10. Chen CT, Kim H, Liska D et al. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol. Cancer Ther. 11(3), 660-669 (2012).
11. Shah MA, Wainberg ZA, Catenacci DV et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE 8(3), e54014-e54022 (2013).
12. Muro K, Ryu M, Yasui H et al. A Phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. J. Clin. Oncol. 30(Suppl.) (2012) (Abstract 4082).
13. Lee HE, Kim MA, Lee HS et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br. J. Cancer 107(2), 325-333 (2012).
14. Spigel DR, Ervin TJ, Ramlau R et al. Final efficacy results from OAM4558g, a randomized Phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 7505).
15. Oliner KS, Rui Tang R, Anderson A et al. Evaluation of MET pathway biomarkers in a Phase II study of rilotumumab or placebo in combination with epirubicin, cisplatin, and capecitabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. J. Clin. Oncol. 30(Suppl.) (2012) (Abstract 4005).
16. Cunningham D, Bang Y, Tabernero J et al. MetGastric: a randomized Phase III study of onartuzumab in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 31(Suppl.) (2013) (Abstract TPS4155).
17. Chan JA, Blaszkowsky LS, Enzinger PC et al. A multicenter Phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann. Oncol. 22(6), 1367-1373 (2011).
18. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14(6), 490-499 (2013).
19. Lordick F, Luber B, Lorenzen S et al. Cetuximab plus oxaliplatin/ leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a Phase II study of the arbeitsgemeinschaft internistische onkologie (AIO). Br. J. Cancer 102(3), 500-505 (2010).
20. Pinto C, Di Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol. 18(3), 510-517 (2007).
21. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 24(30), 4922-4927 (2006).
22. Zenz R, Scheuch H, Martin P et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev. Cell 4(6), 879-889 (2003).
23. Yasui W, Sumiyoshi H, Hata J et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 48(1), 137-141 (1988).
24. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19(10), 2013-2023 (2007).
25. Weiss GJ, Bemis LT, Nakajima E et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 19(6), 1053-1059 (2008).
26. Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 25(22), 3238-3245 (2007).
27. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27(35), 5924-5930 (2009).
28. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National cancer institute of canada clinical trials group study BR.21. J. Clin. Oncol. 26(26), 4268-4275 (2008).
29. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61(5), 673-684 (2012).
30. van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of OS according to tumour KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011).
31. Lee SH, Lee JW, Soung YH et al. BRAF and KRAS mutations in stomach cancer. Oncogene 22(44), 6942-6945 (2003).
32. Kim IJ, Park JH, Kang HC et al. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum. Genet. 114(1), 118-120 (2003).
33. Di Nicolantonio F, Arena S, Tabernero J et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determine their response to everolimus. J. Clin. Invest. 120(8), 2858-2866 (2010).
34. Cepero V, Sierra JR, Corso S et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 70(19), 7580-7590 (2010).
35. Heindl S, Eggenstein E, Keller S et al. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J. Cancer Res. Clin. Oncol. doi:10.1007/s00432-011-1128-4 (2012) (Epub ahead of print).
36. van Cutsem E, Yeh K, Bang Y et al. Phase III trial of everolimus in previously treated patients with advanced gastric cancer: GRANITE-1. J. Clin. Oncol. 30(Suppl. 4) (2012) (Abstracts LBA3).
37. Yoon DH, Ryu MH, Park YS et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br. J. Cancer 106(6), 1039-1044 (2012).
38. Cho D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 5(6), 379-385 (2007).
39. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod. Pathol. 21(3), 231-237 (2008).
40. Templeton AJ, Dutoit V, Cathomas R et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur. Urol. 64(1), 150-158 (2013).
41. Jung EJ, Jung EJ, Min SY et al. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum. Pathol. 43(10), 1559-1566 (2012).
42. Matsumoto K, Arao T, Hamaguchi T et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br. J. Cancer 106(4), 727-732 (2012).
43. André F, Bachelot T, Campone M et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 19(13), 3693-3702 (2013).
44. Xie L, Su X, Zhang L et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19(9), 2572-2583 (2013).
45. Ohtsu A, Shah MA, van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled Phase III study. J. Clin. Oncol. 29(30), 3968-3976 (2011).
46. van Cutsem E, de Haas S, Kang YK et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized Phase III trial. J. Clin. Oncol. 30(17), 2119-2127 (2012).
47. van Cutsem E, Jayson G, Dive C et al. Analysis of blood plasma factors in the AVITA Phase III randomized study of bevacizumab with gemcitabine-erlotinib in patients with metastatic pancreatic cancer. Eur. J. Cancer 47(Suppl. 1), S95-S96 (2011) (Abstract 803).
48. Miles DW, de Haas SL, Dirix LY et al. Biomarker results from the AVADO Phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br. J. Cancer 108(5), 1052-1060 (2013).
49. Hegde PS, Jubb AM, Chen D et al. Predictive impact of circulating vascular endothelial growth factor in four Phase III trials evaluating bevacizumab. Clin. Cancer Res. 19(4), 929-937 (2013).
50. Jubb AM, Miller KD, Rugo HS et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin. Cancer Res. 17(2), 372-381 (2011).
51. Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clin. Cancer Res. 19(11), 2824-2827 (2013).
52. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase 3 trial. Lancet 383(9911), 31-39 (2013).
53. Kim HK, Choi IJ, Kim CG et al. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J. 12(2), 119-127 (2012).
54. Yamada Y, Arao T, Gotoda T et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci. 99(11), 2193-2199 (2008).
55. Shen DW, Liang XJ, Suzuki T, Gottesman MM. Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol. Pharmacol. 69(4), 1383-1388 (2006).
56. Matsubara J, Nishina T, Yamada Y et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br. J. Cancer 98(4), 832-839 (2008).
57. Sirak I, Petera J, Hatlova J et al. Epidermal growth factor receptor as a predictor of tumour response to preoperative chemoradiation in locally advanced gastric carcinoma. Strahlenther. Onkol. 184(11), 592-597 (2008).
58. Ignatiadis M, Singhal SK, Desmedt C et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30(16), 1996-2004 (2012).
59. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007).
60. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16(1), 309-316 (1998).
61. Wei J, Zou Z, Qian X et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br. J. Cancer 98(8), 1398-1402 (2008).
62. Napieralski R, Ott K, Kremer M et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin. Cancer Res. 11(8), 3025-3031 (2005).
63. Moiseyenko VM, Volkov NM, Suspistin EN et al. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Med. Oncol. 30(2), 545-553 (2013).
64. Chen L, Li G, Li J et al. Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term. Cancer Chemother. Pharmacol. 71(4), 921-928 (2013).
65. Jeung HC, Rha SY, Shin SJ et al. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anticancer Drugs 22(8), 801-810 (2011).
66. Ichikawa W, Takahashi T, Suto K et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br. J. Cancer 91(7), 1245-1250 (2004).
67. Ott K, Vogelsang H, Mueller J et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin. Cancer Res. 9(6), 2307-2315 (2003).
68. Oki E, Kakeji Y, Zhao Y et al. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann. Surg. Oncol. 16(9), 2510-2515 (2009).
69. Okines AF, Gonzalez de Castro D, Cunningham D et al. Biomarker analysis in oesophagogastric cancer: results from the REAL3 and Trans MAGIC trials. Eur. J. Cancer pii: S0959-8049(13)00115-9 (2013).
70. Jaiswal BS, Kljavin NM, Stawiski EW et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23(5), 603-617 (2013).
71. Kim HK, Choi IJ, Kim CG et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS ONE 6(2), e16694-e16705 (2011).
72. Malinowsky K, Wolff C, Ergin B, Berg D, Becker KF. Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. J. Cell. Physiol. 225(2), 364-370 (2010).
73. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382(9893), 720-731 (2013).
74. Sprung RW, Martinez MA, Carpenter KL et al. Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue. J. Proteome Res. doi:10.1021/pr300130t (2012) (Epub ahead of print).
75. Kennedy JJ, Abbatiello SE, Kim K et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat. Methods (2013) (Epub ahead of print).